Cargando…

UK prescribing practices as proxy markers of unmet need in allergic rhinitis: a retrospective observational study

Little data on UK prescribing patterns and treatment effectiveness for allergic rhinitis (AR) are available. We quantified unmet pharmacologic needs in AR by assessing AR treatment effectiveness based on the prescribing behaviour of UK general practitioners (GP) during two consecutive pollen seasons...

Descripción completa

Detalles Bibliográficos
Autores principales:	Price, David B, Scadding, Glenis, Bachert, Claus, Saleh, Hesham, Nasser, Shuaib, Carter, Victoria, von Ziegenweidt, Julie, Durieux, Alice M S, Ryan, Dermot
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918055/ https://www.ncbi.nlm.nih.gov/pubmed/27334893 http://dx.doi.org/10.1038/npjpcrm.2016.33

Ejemplares similares

P07 - Treatment load in the therapy management of allergic rhinitis: a UK retrospective database study
por: Carter, Victoria, et al.
Publicado: (2014)

The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey
por: Price, David, et al.
Publicado: (2015)

Optimal management of allergic rhinitis
por: Scadding, Glenis K
Publicado: (2015)

Short and long-term safety of MP29-02*: a new therapy for the treatment of allergic rhinitis
por: Price, David, et al.
Publicado: (2013)

A new therapy (MP29-02*) effectively targets the entire seasonal allergic rhinitis symptom complex
por: Price, David, et al.
Publicado: (2013)

Evaluating the real-life effect of MP-AzeFlu on asthma outcomes in patients with allergic rhinitis and asthma in UK primary care
por: De Jong, Hilda J.I., et al.
Publicado: (2020)

A new therapy (MP29-02*) effectively controls nasal symptoms of seasonal allergic rhinitis irrespective of severity
por: Scadding, Glenis, et al.
Publicado: (2013)

A new therapy (MP29-02*) provides effective relief from all individual nasal and ocular symptoms of seasonal allergic rhinitis
por: Hellings, Peter, et al.
Publicado: (2013)

MP29-02*’s advanced delivery system contributes to its efficacy in patients with moderate/severe seasonal allergic rhinitis
por: Scadding, Glenis, et al.
Publicado: (2015)

A new efficacy parameter (complete/near complete symptom relief) in allergic rhinitis management: results with a new therapy MP29-02*
por: Bousquet, Jean, et al.
Publicado: (2013)

A new therapy (MP29-02*) effectively treats patients with seasonal allergic rhinitis who suffer most from the bothersome nasal symptom of congestion
por: Bachert, Claus, et al.
Publicado: (2013)

A new allergic rhinitis therapy (MP29-02*) provides nasal and ocular symptom relief days faster than current firstline monotherapies
por: Hellings, Peter, et al.
Publicado: (2015)

Seasonal allergic rhinitis: fluticasone propionate and fluticasone furoate therapy evaluated
por: Kariyawasam, Harsha H, et al.
Publicado: (2010)

EUFOREA Comment on a Misleading Allergic Rhinitis Report [Letter]
por: Scadding, Glenis K, et al.
Publicado: (2023)

Rhinitis and Sinusitis
por: Scadding, Glenis K.
Publicado: (2008)

A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress
por: Hellings, Peter W., et al.
Publicado: (2015)

Allergic rhinitis and asthma symptoms in a real-life study of MP-AzeFlu to treat multimorbid allergic rhinitis and asthma
por: Price, David, et al.
Publicado: (2020)

Multicentre, non-interventional study to assess the profile of patients with uncontrolled rhinitis prescribed a novel formulation of azelastine hydrochloride and fluticasone propionate in a single spray in routine clinical practice in the UK
por: Scadding, Glenis, et al.
Publicado: (2017)

Assessment of disease control in allergic rhinitis
por: Demoly, Pascal, et al.
Publicado: (2013)

Using magnetic resonance imaging to quantify the inflammatory response following allergen challenge in allergic rhinitis
por: Leaker, Brian R., et al.
Publicado: (2015)

Upper Airway Disease: Rhinitis and Rhinosinusitis
por: Scadding, Glenis K., et al.
Publicado: (2012)

MP-AzeFlu Improves the Quality-of-Life of Patients with Allergic Rhinitis
por: van Weissenbruch, Ranny, et al.
Publicado: (2020)

Rhinitis, sinusitis and ocular disease – 2091. The MSYPQ: repeatability and applicability to rhinitis/rhinosinusitis
por: Sami, Amtul Salam, et al.
Publicado: (2013)

The need for patient-focused therapy for children and teenagers with allergic rhinitis: a case-based review of current European practice
por: Santos, Alexandra F, et al.
Publicado: (2015)

Allergic Rhinitis in Childhood and the New EUFOREA Algorithm
por: Scadding, Glenis Kathleen, et al.
Publicado: (2021)

Nasal IgE in subjects with allergic and non-allergic rhinitis
por: Eckrich, Jonas, et al.
Publicado: (2020)

Management of persistent allergic rhinitis: evidence-based treatment with levocetirizine
por: Mullol, Joaquim, et al.
Publicado: (2005)

Higher efficacy of rupatadine 20 mg and 10 mg versus placebo in patients with perennial allergic rhinitis: a pooled responder analysis
por: Valero, Antonio, et al.
Publicado: (2020)

Unmet Primary Physicians' Needs for Allergic Rhinitis Care in Korea
por: Yang, Hyeon-Jong, et al.
Publicado: (2017)

Identification of gaps in the current allergic rhinitis guidelines and how these can be filled
por: Bousquet, Jean, et al.
Publicado: (2015)

Seasonal distribution of inhaled allergens in allergic asthma patients with or without allergic rhinitis
por: Tian, Ruxian, et al.
Publicado: (2022)

Fexofenadine: review of safety, efficacy and unmet needs in children with allergic rhinitis
por: Meltzer, Eli O., et al.
Publicado: (2021)

Unmet needs in allergic rhinitis: international survey on management of allergic rhinitis by physician and patient. The physicians' view (ISMAR 2 study)
por: Baena-Cagnani, Carlos E, et al.
Publicado: (2015)

Unmet needs in allergic rhinitis: international survey on management of allergic rhinitis by physician and patient: the optimal management (ISMAR 2 study)
por: Baena-Cagnani, Carlos E, et al.
Publicado: (2015)

A new intranasal therapy (MP29-02*) is more effective than current firstline therapy regardless of season, symptom or severity.
por: Bachert, Claus, et al.
Publicado: (2015)

Correction: Fexofenadine: review of safety, efficacy and unmet needs in children with allergic rhinitis
por: Meltzer, Eli O., et al.
Publicado: (2022)

Real‐world benefits of allergen immunotherapy for birch pollen‐associated allergic rhinitis and asthma
por: Wahn, Ulrich, et al.
Publicado: (2018)

Single nucleotide polymorphisms in thymic stromal lymphopoietin gene are not associated with allergic rhinitis susceptibility in Chinese subjects
por: Zhang, Yuan, et al.
Publicado: (2012)

The SP‐TLR axis, which locally primes the nasal mucosa, is impeded in patients with allergic rhinitis
por: Larsson, Olivia, et al.
Publicado: (2021)

Allergic respiratory disease care in the COVID-19 era: A EUFOREA statement
por: Scadding, Glenis K., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ius0919sv4usngiphnnlubq20k